In a significant industry development, Japanese beauty giant Shiseido’s Americas subsidiary has finalized a pivotal agreement to acquire DDG Skincare Holdings, the proud proprietor of the renowned Dr Dennis Gross Skincare brand. The undisclosed yet strategic transaction is poised to bolster Shiseido’s position in the prestige skincare market, enhancing its core offerings, including the esteemed brands Shiseido and Clé de Peau Beauté.
Dr Dennis Gross Skincare, founded in 2000 by the distinguished Dr. Dennis Gross, a former skin cancer researcher and practicing dermatologist, along with his wife, Carrie Gross, has left an indelible mark on the beauty industry. Through science-led innovations, the brand has redefined skincare, earning recognition for its distinctive and highly effective products rooted in a philosophy of research, dermatology, and technology.
This acquisition seamlessly aligns with Shiseido’s innovation-centric corporate mission, providing a synergistic addition to the company’s skin beauty strategic framework. Beyond fortifying Shiseido’s core prestige skincare business, this move catapults Dr Dennis Gross Skincare onto a global stage, leveraging Shiseido’s expansive support network, commercial expertise, and research and development capabilities.
Masahiko Uotani, Chairman and CEO of Shiseido, underscores the transaction’s significance, stating, «This aligns with Shiseido’s 2030 goal of becoming a personal beauty wellness company.» He emphasizes the shared core values in scientific and innovative beauty approaches and a people-first culture.
Ron Gee, President/CEO of Shiseido Americas and Global M&A Leader, lauds the innovative and disruptive approach of Dr Dennis Gross Skincare in the beauty industry. Recognizing the brand’s credibility and effectiveness in product delivery through research, accessibility, and education, Gee sees this move as a transformative moment.
Dr. Dennis Gross himself endorses the acquisition, stating that Shiseido is «the ideal home» for the label. The transaction, subject to customary regulatory approvals and closing conditions, is anticipated to conclude in Q1, marking a pivotal moment for both Shiseido and Dr Dennis Gross Skincare in the dynamic world of prestige skincare.
